Results from a retrospective analysis of the phase III SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer who had a poor prognosis.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe